...sees on the horizon is the FDA clearing a path for companies to make “biosimilars” or generic-like copies of branded biotech drugs like Amgen’s Epogen for anemia. If that happens in another year or two, it could put pressure on the worldwide capacity for biotech...

...countless proposals for stricter regulation. But a new trend in campaign contributions emerges from data reported by Pfizer, Amgen, Johnson & Johnson, other companies and their trade associations. In the 2008 election cycle, pharmaceutical companies their...

...over the weekend, with several new surprises, including a three-day women’s stage race held in February in conjunction with the Amgen Tour of California. Other new additions include the Dana Point Grand Prix of Cycling, held April 26, the renamed Oregon Pro...

...upheld the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen's patents. About Amgen Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology...

...earning guidance and it supplies the tools and systems used in the drug discovery process, genetic analysis, and diagnostics. I like Amgen (AMGN) in the rapidly consolidating biotech space and Teva Pharma (TEVA) as the generic drug industry leader, which also...

...School in Daleville, has been named a science fellow by the National Science Teachers Association,, in partnership with the Amgen Foundation; Agilent Technologies Foundation; Astellas Pharma US Inc.; and Bayer Corporation. Some185 new middle and secondary...

...its Mircera anemia drug, which would compete against Amgen’s Epogen and Aranesp meds. Last year, a jury found that Roche violated Amgen patents. A Roche spokeswoman says the drugmaker will “continue to pursue opportunities to appeal this matter and that Roche...

...on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development...

...vital medicines, visit www.amgen.com. Amgen Emma Hurley, 805-447-7845 (media) Arvind Sood, 805-447-1060 (investors) wwwext.amgen.com/ - Today the United States (U.S.) Court of Appeals for the Federal Circuit issued a ruling that affirms the preliminary injunction...

...of the Dow Jones which declined by 2% and the NASDAQ Composite which gained less than 1% -- Shares of biotech heavyweights, Amgen (NASDAQ: AMGN) and Genentech (NYSE: DNA) fell 21% and 11% respectively in the second half of 2007 -- The Canadian biotech...